Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients.
about
Captopril and atenolol combined with hydrochlorothiazide in essential hypertension.John H. Laragh, MD: clinician-scientist.Control of essential hypertension with captopril, an angiotensin converting enzyme inhibitor.Long-term efficacy of angiotensin-converting-enzyme inhibition with captopril in mild-to-moderate essential hypertension.Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension.Long-term experience with captopril in severe hypertension.Heart rate control in hypertensive patients treated by captopril.Splint renal function after captopril in unilateral renal artery stenosis.Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertensionCaptopril in renovascular hypertension: long-term use in predicting surgical outcome.Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propranolol.Factors related to first dose hypotensive effect of captopril: prediction and treatment.Effect of captopril (SQ 14225) on blood pressure, plasma renin activity and angiotensin I converting enzyme activity.BW A575C, a chemically novel agent with angiotensin converting enzyme inhibitor and beta-adrenoceptor-blocking properties.Role of renin secretion and kidney function in hypertension and attendant heart attack and stroke.Low-grade fever after prosthetic valve insertion and captopril therapy: an iatrogenic cause.The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure.Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review.Relation of plasma renin activity to the antihypertensive effect of MK 421 in the rat.Captopril: clinical pharmacology and benefit-to-risk ratio in hypertension and congestive heart failure.The involvement of arachidonic acid metabolism in the control of renin release.Effects of captopril in animal models of hypertension.Captopril-induced skin eruptions.Converting enzyme inhibitors in hypertension and heart failure.The renin system for understanding human hypertension: evidence for blood pressure control by a bipolar vasoconstriction-volume mechanism. Prorenin as a determinant of renin secretion.Correlation between plasma concentration of cilazapril and haemodynamic and hormonal effects in healthy man.Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.The effect of acute and chronic captopril therapy on baroreflex function in manAngiotensins II and III prevent captopril-induced renin release in the rat.RHC 3659: a new orally active angiotensin converting enzyme inhibitor in normal volunteers.Effects of captopril on neurosecretion and vascular responsiveness in hypertension.The effects of captopril (SQ14,225) on the systemic and coronary haemodynamics of the intact anaesthetized dog.The renin system for long-term control over vasoconstriction and sodium-volume homeostasis in the spectrum of hypertension: three new frontiers in research.Studies on the mechanism of the enhancement of the antihypertensive activity of captopril by a diuretic in spontaneously hypertensive rats.Captopril in mild and severe hypertension.
P2860
Q28367116-9707B9DE-9B65-4BE3-8DD1-3480DDD9D8DBQ34016361-62DE4A9D-4787-4CEE-A068-F53A61337980Q34448560-2F9ECFAA-B066-4C20-AC83-25BB29F18F7FQ34511327-0F77AE15-A3B8-4D16-B240-55F390F88BE4Q34511373-90A94AFB-28D5-4C3D-9745-226AE0260CC5Q34511406-13843B0C-86A5-4D8D-86FF-129B006679A0Q34511533-8860C462-A5AB-4355-89D6-A215DC97FE14Q34549802-9535FBB7-016E-428F-8E3A-44E76DFA0C52Q34621390-F36181B3-770C-4327-8D60-DFBE5AB4335FQ34750266-DE562E83-8632-4958-9541-8914F42F7889Q34750303-0E5F1B4C-210A-469D-A262-B62EAC7C83F9Q34991422-C4FB1403-BB51-4FCF-B0FF-352B490FEABCQ35228127-5985F08F-99EF-4D52-8784-06628401F323Q35887503-554783C8-03ED-4603-AF7A-B7CB035060A5Q35898763-C7F91023-B7BA-4EDD-8DDC-972812222CB3Q36728267-C76F6848-D90C-4967-9FA8-45FC411125C4Q37936785-795EE7D6-C58E-4932-843C-DA41A7B2DD7DQ38715065-20B5FCCA-10CF-468C-BC59-CDA0CD8496C3Q39856276-0558801E-4AD5-4CB0-94A5-2BF9EF028C04Q40256137-BAE4D09D-5219-4F7A-B74A-072973DFDADBQ40285988-4D55E218-4C0F-43E8-A7A6-FD85A08B1137Q40292890-1ED8787B-704F-4D3C-B2A3-A477A72BCDDFQ40845712-CA53299E-FB57-410D-B422-802960AF7913Q41302299-D580C42A-009D-48F7-94F7-BCE1EC86F75FQ41465055-89D7DD1A-C584-4E47-AE59-F0093340C15FQ42032187-F7637DCE-9627-4D96-9591-F1A3463DF346Q42098372-6C3746EC-77A8-487D-BD19-01E076D32F20Q42151850-3232E469-A387-4349-B9AA-5F88295456DAQ42207157-8CDF5496-5A15-465C-876D-2190254E4A52Q43241278-359FDF48-BE39-435D-9246-4849397AED07Q44153475-84A84A68-6DC4-48CD-ADCF-E9CA0AF8049EQ51870424-DE9C04B6-39DA-4A4B-9427-CB930D6591A1Q54506404-FFF14A0A-7296-410F-99B4-A7628392F05BQ54526156-CA467D00-98AC-4D64-938D-CFF44BEDBB0FQ54548496-D449FF6D-2755-4232-9A71-281BC2022744
P2860
Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients.
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
1978年论文
@zh
1978年论文
@zh-cn
name
Clinical experience with block ...... ril) in hypertensive patients.
@en
type
label
Clinical experience with block ...... ril) in hypertensive patients.
@en
prefLabel
Clinical experience with block ...... ril) in hypertensive patients.
@en
P2093
P1476
Clinical experience with block ...... ril) in hypertensive patients.
@en
P2093
P304
P356
10.1016/0033-0620(78)90025-7
P577
1978-11-01T00:00:00Z